natgillin/translations-raw huggingface dataset:
The method of claim 18, wherein said salt is selected from the group consisting of a sodium salt, potassium salt, magnesium salt, or calcium salt, of citric acid, fumaric acid, malic acid, phosphoric acid, or mixture thereof. 
Postupak u skladu s patentnim zahtjevom 17, gdje navedenu sol se bira iz skupine koju čine natrijeva sol, kalijeva sol, magnezijeva sol ili kalcijeva sol limunske kiseline, fumarne kiseline, jabučne kiseline, fosforne kiseline, ili njihova smjesa.
Further, the fusion protein may additionally comprise a C-terminal element, having a length of e.g. 1-50, preferably 10-30 amino acids which may include or connect to a recognition/purification domain, e.g. a FLAG domain, a Strep-tag or Strep-tag II domain and/or a poly-His domain. 
Polipeptid u skladu s bilo kojim od zahtjeva 1-6 koji dodatno sadrži domenu N-terminalnog signalnog slijeda, koji može sadržavati mjesto cijepanja za proteazu, i/ili koji dodatno sadrži C-terminalni element koji može sadržavati i/ili se spajati na domenu prepoznavanja/pročišćavanja.
The sealing device of claim 8, wherein annular metal body seal element has a coating of dielectric material. 
Izolacijski sustav prema zahtjevu 1, naznačen time, da spomenuti prstenasti metalni zaptivni element (52) ima oblogu od dielektričnog materijala.
A dosage form according to claim 1, which is in the form of a tablet. A dosage form according to claim 1, which is in multiparticulate form. 
Oblik davanja lijeka prema patentnom zahtjevu 1, naznačen time, da je u obliku tablete.
The bispecific antibody of claim 6, wherein the aglycosylation site mutation is selected from the group consisting of N297G, N297A, L234A, L235A, and D265A. 
Bispecifično protutijelo prema patentnom zahtjevu 8, naznačeno time, da je supstitucijska mutacija odabrana iz skupine koju čine N297G, N297A, L234A, L235A i D265A.
The high protein, fruit-flavoured beverage according to embodiment 1, wherein the denatured whey protein composition is: 
Visokoproteinski napitak s voćnom aromom u skladu s patentnim zahtjevom 1, naznačen time što je pripravak denaturiranog proteina sirutke:
Experiments were performed to see how much of the total SDS was associated with IL-2 and how much remains free in solution. 
Eksperimenti su se izvodili da bi se vidjelo koliko je od ukupnog SDS bilo združeno s IL-2, a koliko je preostalo slobodno u otopini.
After stirring at room temperature for 1 hour, the reaction was quenched with 1N HCl (100 mL). 
Nakon miješanja na sobnoj temperaturi tijekom jednog sata, reakcija se prekine s IN HCI (100 mL).
Use according to claim 12, characterized in that said antibiotic or other antimicrobial agent is selected from aminoglycosides, tetracyclines, macrolides, quinolones, sulfonamides alone or combined with diaminopyridines, penicilline compounds, cephalosporins and other B-lactam antibiotics, lincosamides, antiprotozoarians, antibacterials, antiseptics and salts thereof. 
Upotreba u skladu s patentnim zahtjevom 12, naznačena time što navedeni antibiotik ili antimikrobno sredstvo se bira između aminoglikozida, tetraciklina, makrolida, kinolona, sulfonamida samih ili u kombinaciji s diaminopiridinima, penicilinskih spojeva, cefalosporina i drugih B-laktamskih antibiotika, linkozamida, antiprotozoika, antibakterijskih sredstava, antiseptika i njihovih soli.
at least one internucleoside linkage of said oligonucleotide is a modified internucleoside linkage, optionally wherein each internucleoside linkage is a phosphorothioate internucleoside linkage; 
Spoj za upotrebu prema zahtjevu 5, pri čemu bar jedna internukleozidna veza modificiranog oligonukleotida je modificirana internukleozidna veza, pri čemu opcionalno svaka internukleozidna veza modificiranog oligonukleotida je modificirana internukleozidna veza.
Combined organic extracts are washed with brine and dried over sodium sulphate. 
Pomiješane organske ekstrakte ispere se slanom vodom, te osuši preko natrijevog sulfata.
The ASM according to any one of paragraphs 2, 17 to 29 and 34 to 37, in which the mutation is L302P, H421Y and R496L. 
KSM za uporabu u skladu s patentnim zahtjevom 17, pri čemu je navedena mutacija L302P, H421Y ili R496L.
X is L -Y-glutamyl or L -Y-glutamylglycyl; and Y is H, optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted aryl, optionally substituted arallyl, optionally substituted heteroaryl, or optionally substituted heteroaralkyl; 
Y je H, po izboru supstituirani alkil, po izboru supstituirani heteroalkil, po izboru supstituirani aril, po izboru supstituirani aralkil, po izboru supstituirani, heteroaril ili po izboru supstituirani heteroaralkil; i
The monoclonal antibody or antigen binding fragment thereof of claim 1, which binds to at least four CC chemokines selected from the group consisting of CCL3/MIP-1a, CCL4/MIP-1B, CCL5/RANTES, and CCL23/MPIF-1, and which does not bind to CCL2/MCP-1, comprising a heavy and light chain CDR sequence combination (HCDR1/HCDR2/HCDR3/LCDR1/LCDR2/LCDR3) of SEQ ID NOS: 13/14/15/18/19/20, or which competes for binding to at least four CC chemokines selected from CCL3/MIP-1a, CCL4/MIP-1B, CCL5/RANTES, and CCL23/MPIF-1, with an antibody or antigen binding fragment comprising a heavy and light chain CDR sequence combination of SEQ ID NOS: 13/14/15/18/19/20. 
Monoklonsko protutijelo, ili njegov fragment koji veže antigen, u skladu s patentnim zahtjevom 1, naznačeno time, da se veže na najmanje četiri CC kemokina odabranih iz skupine koja se sastoji od CCL3/MIP-1a, CCL4/MIP-1B, CCL5/RANTES, i CCL23/MPIF-1, i koji se ne veže na CCL2/MCP-1, koji sadrži kombinaciju CDR sekvence teškog i lakog lanca (HCDR1/HCDR2/HCDR3/LCDR1/LCDR2/LCDR3) od SEQ ID NOS: 13/14/15/18/19/20, ili koji se natječe za vezanje na najmanje četiri CC kemokina odabranih iz CCL3/MIP-1a, CCL4/MIP-1B, CCL5/RANTES i CCL23/MPIF-1, s antitijelima ili fragmentom koji veže antigen i koji sadrži kombinacije CDR slijeda teškog i lakog lanca SEQ ID NOS: 13/14/15/18/19/20.
According to this aspect there is provided a process for preparing intermediate (XI), starting from a hydroxycyclopentyl bis-ester of formula (Va), by either 
Postupak za pripravu spoja formule (XI), ili njegove soli, koji započinje od hidroksiciklopentil bis-estera formulo (Va), bilo sa:
Use according to any one of claims 17 to 20, wherein the fluid provided via the lance tube has a flow rate of from about 0.05 l/min to about 5 l/min, preferably of form about 0.1 l/min to about 4 l/min, more preferably of from about 0.19 l/min to about 2.7 l/min. 
Uporaba prema bilo kojem od zahtjeva 16 do 19, naznačena time da fluid doveden putem dugačke cijevi ima protok od oko 0.05 I/min do oko 5 Y/min, poželjno od oko 0.1 l/min do oko 4 I/min, poželjnije od oko 0.191/min do oko 2.7 I/min. HR P20170626 T1
The method of claim 2, wherein said decrease of the deformylation of formyl-THF is achieved by the attenuation of the expression of the gene purU. 
Metoda iz patentnog zahtjeva 1, naznačena time da je rečeno smanjivanje deformilacije formil-THF postignuto smanjivanjem ekspresije gena purU.
or a part structure of general formula SF-III wherein x represents 0, 1 or 2; 
ili dio strukture s općom formulom SF-III [image] pri čemu x predstavlja 0, 1 ili 2;
0.22 Total Capsule Weight Pharmaceutical dosage form according to claim 4 in form of a soft gelatin capsule containing 200 mg of active substance free base equivalent, selected from the following compositions A, B and C: 
Ukupna masa kapsule 7. = Farmaceutski dozni oblik prema zahtjevu 4, naznačen time, da je u obliku mekane želatinske kapsule koja sadrži 100 mg djelatne tvari, ekvivalenta slobodne baze, koji je odabran od sljedećih sastava A, B 1 C:
Compounds according to claims 1 to 3 for use as a pharmaceutical. 
Spojevi prema zahtjevima 1 do 2, naznačeni time, da se upotrebljavaju za liječenje epilepsije ili shizofrenije.
These sealing means 17 cooperates with the inwardly facing surface of the lower part of the outer wall 16 of the base unit 3, in order to provide a hermetical sealing as described above for the embodiments as illustrated with figs. 2-5b. 
To sredstvo 17 za brtvljenje djeluje zajedno s prema unutra okrenutom površinom donjeg dijela vanjske stijenke 16 osnovne jedinice 3, da se osigura hermetičku zabrtvljenost, kao što je gore opisano za izvedbe prikazane na slikama 2- 5b.
identifying the peptide of which CTL inducibility is the same as or higher than the one of a peptide consisting of the original amino acid sequence. 
(v) identificiranja peptida čija je inducibilnost citotoksične T-stanice ista kao ili veća nego kod peptida koji ima izvorni aminokiselinski slijed.
A system according to claim 45, wherein the receptacle is provided in a form of an enclosing member. 
Sistem prema patentnom zahtjevu 18, pri čemu je posuda (108) izvedena u obliku obuhvatnog elementa (108).
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl)amide and as component (B) fenpropidin. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1 Hpirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-iljamid, te kao komponentu (B) spoj koji je izabran između slijedećeg: difenokonazola, propikonazola, kiprokonazola i epoksikonazola.
A compound of general formula (I), or a pro-drug, stereoisomer, pharmaceutically acceptable salt or hydrate thereof, wherein, 
3 a au? Na Å oče M E oo ili stereoizomer, farmaceutski prihvatljiva sol ili hidrat istog, pri čemu
When the animal remained inactive, the speed was below threshold 2, the movement was considered as inactivity. 
Kada su životinje ostale inaktivne,brzina je bila ispod praga 2, kretanje je smatrano kao inaktivnost.
o a predetermined number of distributors (33) of a thermoregulation fluid, positioned outside the mould (2) and configured for directing the thermoregulation fluid at least towards predetermined portions of an external lateral surface of the mould (2) itself, 
zadani broj razdjelnika (33) termoregulacijskog fluida, smješten izvan kalupa (2) i konfiguriran za usmjeravanje termoregulacijskog fluida u najmanju ruku prema zadanim dijelovima vanjske bočne površine samog kalupa (2), 9
The reaction mixture is concentrated under vacuum and the residue dissolved in ethyl acetate (50 ml, 100 ml/mmol). 
Reakcijska smjesa je uparena pod vakuumom a ostatak je otopljen u etil-acetatu (50 mL, 100 mL/mmol).
Amisulpride for use according to any of claims 1 to 3, to be administered by oral, transdermal, sublingual or inhaled administration. 
Amisulprid, namijenjen upotrebi u skladu s patentnim zahtjevom 1 ili 2, naznačen time što se primjenjuje rektalnom, intranazalnom, bukalnom, oralnom, transdermalnom, sublingvalnom ili inhalacijskom primjenom.
a plug (36, 136, 236, 436, 636) positioned at least partially in the interior passage of the neck of the container and having a through passage (66, 266, 466, 666) and a radially outer surface (62, 162, 262, 462) radially inward of the inner surface of the retainer, and 
444. 544) radijalno prema unutra unutarnje površine grla: zatvarač (36. 136, 236, 436, 636), koji se u najmanju ruku dijelom nalazi u unutarnjem prolazu grla spremnika i ima prolaz (66, 266, 466, 666) i radijalnu vanjsku površinu (62.
One preferred mixture comprises from 40 to 60 wt % difluoromethane and from 60 to 40 wt % pentafluoroethane. Another preferred mixture comprises from 45 to 55 wt % difluoromethane and from 55 to 45 wt % pentafluoroethane. 
Pripravak rashladnog plina prema zahtjevu 1, naznačen time da difluormetan i pentafluoretan imaju udio mješavine od 45 do 55 tež.% difluormetana i od 55 do 45 tež.% pentafluoretana.
The peptide according to Claim 1, wherein said peptide includes non-peptide bonds. 
peptida u skladu s a), pri čemu navedeni peptid uključuje nepeptidne veze, i
The method according to claim 12, wherein the particulate polylactic acid obtained in step i) is contacted with air or steam having a temperature of 60-160° C. in step ii). 
Postupak u skladu s patentnim zahtjevom 14, naznačena time što se partikuliranu polimliječnu kiselinu dobivenu u koraku i) stavi u koraku ii) u kontakt sa zrakom ili vodenom parom s temperaturom od 60 do 160*C.
is selected from the group consisting of H, C1-C6-alkyl, C1-C6-alkoxy, halogen; 
Bo Ba D je ili odabran iz skupine koja se sastoji od D1, D2, D3:
Any compound that can be converted in vivo to provide the bioactive agent (i.e., the compound of formula I) is a prodrug. 
Prolijek je bilo koji spoj koji se in vivo može konvertirati za osiguravanje bioaktivnog agensa (npr., spoj formule I).
is phenyl or pyridyl, which is para-substituted by Hal and/or meta-substituted by Hal or LA, and pharmaceutically acceptable salts, solvates, solvates of salts, thereof. 
R> je fenil ili piridil, koji je para-supstituiran s Hal i/ili meta-supstituiran s Hal ili LA, i njihove farmaceutski prihvatljive soli, solvati ili solvati soli.
The pharmaceutical composition of claim 1, wherein the composition contains the corresponding montelukast sulfoxide wherein the corresponding montelukast sulfoxide of in the composition does not increase by more than 1% by weight from the initial amount of montelukast after storage at about 40°C and about 75% relative humidity for 3 months. 
Farmaceutska kompozicija prema patentnom zahtjevu 1, naznačena time što kompozicija sadrži odgovarajući montelukast sulfoksid, pri čemu se odgovarajući montelukast sulfoksid u kompoziciji ne povećava za više od 1 težinski % od početne količine montelukasta poslije čuvanja na oko 40*C i oko 75% relativne vlažnosti u trajanju od 3 mjeseca.
Yet more specifically, the discontinuous epitope consists of the amino acid sequence of SEQ ID NO:25, the amino acid sequence of SEQ ID NO: 26 and the amino acid sequence of SEQ ID NO: 27. According to one embodiment, an antibody or an antigen-binding fragment thereof the present invention includes: 
(ii) aminokiselinske sekvence od CDR1, CDR2 i CDR3 varijabilnog područja slabog lanca pojedinačno uključuju odnosnim redom: a) aminokiselinsku sekvencu od SEQ ID NO: 16; b) aminokiselinsku sekvencu od SEQ ID NO:17; 1 c) aminokiselinsku sekvencu od SEQ ID NO: 18.
Overview of the solubility of selected Aramchol salts 
Datum objave europske prijave patenta:
a time-frequency deinterleaver (r709, r710) configured to time-frequency deinterleave constellation values corresponding to PLP data; 
dio za raspletanje vremena-frekvencije konfiguriran za raspletanje vremena-frekvencije konstelacijskih vrijednosti koje odgovaraju PLP podatku;
The pyridone derivative, or a salt thereof, according to claim 8, wherein R4 in the formula (I) represents a methyl group. 
Derivat piridona ili njegova sol prema patentnim zahtjevima 1 do 8, naznačen time da je R4 u formuli (I) metil grupa.
is phenyl, pyrimidinyl, imidazolyl, triazolyl, tetrazolyl, thiazolyl, thiadiazolyl, pyridinyl, oxazolyl, oxadiazolyl, pyrazolyl, pyridazinyl, triazinyl or pyrazinyl each optionally substituted with 1 to 3 substituents independently selected from methyl, ethyl, methoxy, cyano or -C(O)NH2; and L is a direct bond or O; or a pharmaceutically acceptable salt thereof. 
je fenil, pirimidinil, imidazolil, triazolil, tetrazolil, tiazolil, tiadiazolil, piridinil, oksazolil, oksadiazolil, pirazolil, piridazinil, triazinil ili pirazinil od kojih je svaki izborno supstituiran s 1 do 3 supstituenta, koje se neovisno bira između metila, etila, metoksi, cijano ili -C(O)NH2; a L je izravna veza ili O; ili njegova farmaceutski prihvatljiva sol.
Rb2 and Rb6 are independently selected from hydrogen, methyl and fluorine; Rb3 and Rb5 are independently selected from hydrogen, halogen, C1-C6 alkyl, C3-C6 cycloalkyl, and C1-C6 alkoxy; and 
Rb; i Rb; su neovisno odabrani od sljedećih: vodik, metil 1 fluor; Rb; i Rbs su neovisno odabrani od sljedećih: vodik, halogen, Cy-Cg alkil, Cs-Ce cikloalkil i Cy-Cg alkoksi; i
electrolytic deposition of a metal onto the portion of the surface comprising the reduced metal coordination complex by the steps of: 
Postupak prema zahtjevu 1, naznačen time, da postavljanje konduktivnog materijala na površinu, obuhvaća jedan od sljedećih koraka:
In one embodiment, the progeny T cells in the human comprise a memory T cell. In one embodiment, the T cell is an autologous T cell. 
T stanica za upotrebu prema patentnom zahtjevu 10, naznačena time što primijenjena genetički konstruirana T stanica proizvodi potomstvo T stanica u čovjeku koje sadrži memorijsku T stanicu.
In particular, deterioration in gait was substantially arrested or slowed during this period, and the incidences of involuntary movements such as involuntary chorea, tremors and twitches in the Isomer B-treated mice were no worse after 21 days than they had been prior to administration of the Isomer B. It is conceivable that by repeating the administration of Isomer B at appropriate intervals (which was not done in the tests), the development of the symptoms could be arrested or slowed still further. 
Točnije, pogoršanje u hodu je potpuno zaustavljeno ili usporeno za vrijeme navedeog razdoblja te pojave nehotičnih pokreta poput nehotične koreje, drhtanja ili grčeva kod miševa tretiranih Izomerom B nisu bile lošije nakon 21 dan nego li su bile prije primjene Izomera B. Razumljivo je da ponavljanjem primjene Izomera B u odgovarjućim slo El E
A polypeptide comprising a first binding domain which is an antibody capable of binding to an epitope of human and Callithrix jacchus, Saguinus oedipus or Saimiri sciureus CD3e chain, wherein the epitope is part of an amino acid sequence comprised in the group consisting of SEQ ID NO:2, 4, 6, or 8 and comprises at least the amino acid sequence Gln-Asp-Gly-Asn-Glu, and a second binding domain capable of binding to EGFR, Her2/neu or IgE of a human and/or a non-chimpanzee primate. 
Polipeptid, naznačen time što sadrži prvu vežuću domenu, koja je protutijelo koje se može vezati na epitop iz CD3e lanca iz čovjeka i majmunskih vrsta Callithrix jacchus, Saguinus oedipus ili Saimiri sciureus, gdje je epitop dio aminokiselinskog slijeda koji se nalazi u skupini koju čine SEQ ID NO:2, 4, 6, ili 8 i u najmanju ruku sadrži aminokiselinski slijed Gln-Asp-Gly-Asn-Glu, a druga vežuća domena se može vezati na EGFR, Her2/neu ili IgE iz čovjeka i/ili primata koji nije čimpanza.
Ink cartridge (3) for an inkjet printer (2), comprising 
Uložak za tintu (3) za tintni pisač (2), koji ima donju površinu (35) i prednju površinu (33);
Process B typically gives rise to dihydrotetrabenazine isomers in which the hydrogen atoms at the 2- and 3-positions have a cis relative orientation. 
Postupak B obično daje izomere dihidrotetrabenazina u kojima atomi vodika u položajima 2- 1 3- imaju cis relativnu orijentaciju.
The pharmaceutical composition according to claim 9, used in the preparation of a medicament, with this medicament being used to treat sleep disorders, stress, anxiety, seasonal affective disorder, severe depression, cardiovascular diseases, digestive system diseases, insomnia and fatigue brought on by jet lag, schizophrenia, phobias, or depression. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 9, naznačen time, da se koristi za pripravu lijeka, pri čemu se taj lijek upotrebljava za liječenje poremećaja spavanja, stresa, anksioznosti, sezonskih afektivnih poremećaja, teške depresije, kardiovaskularnih bolesti, bolesti probavnog sustava, nesanice i umora uslijed vremenske razlike, shizofrenije, fobija ili depresija.
the antibody or antibody fragment thereof competitively inhibitis binding of an antibody or fragment thereof comprising a variable light chain comprising the amino acid sequence of SEQ ID NO: 1 and a variable heavy chain comprising the amino acid sequence of SEQ ID NO: 2, the antibody or antibody fragment thereof comprises a variable light chain comprising the amino acid sequence of SEQ ID NO: 1 or an amino acid sequence being at least 95% identical to SEQ ID NO: 1 and comprises a variable heavy chain comprising the amino acid sequence of (SEQ ID NO: 2 or an amino acid sequence being at least 95% identical to SEQ ID NO: 2, 
Bispecifično antitijelo ili njegov bispecifični fragment antitijela koji se specifično veže na IL-13 i IL-4, naznačeno time da navedeno bispecifično antitijelo ili njegov bispecifični fragment antitijela sadrži dva laka lanca sa strukturom N-VLhB-B13-poveznica-VLhBD4-8-CL-C i dva teška lanca sa strukturom N-VHhB-B13-poveznica-VHhBD4-8-CH1-CH2-CH3-C, pri čemu VLhB-B13 sadrži sekvencu aminokiseline SEQ ID NO: 1, pri čemu VLhBD4-8 sadrži sekvencu aminokiseline SEQ ID NO: 3, pri čemu VHhB-B13 sadrži sekvencu aminokiseline SEQ ID NO: 2, pri čemu VHhBD4-8 sadrži sekvencu aminokiseline SEQ ID NO: 4, te pri čemu svaka poveznica je peptidna poveznica koja ima sekvencu aminokiseline koja sadrži SEQ ID NO: 6.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide and as component (B) a compound selected from difenoconazole, ipconazole, prothioconazole, tebuconazole, epoxiconazole, propiconazole, and cyproconazole. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1Hpirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-il)amid, le kao komponentu (B) fluopiram.
a sheath, said sheath substantially or completely surrounding said core, said sheath comprising ethylene vinyl acetate copolymer; and 
(b) omotač, navedeni omotač uglavnom ili potpuno okružuje navedenu jezgru, te navedeni omotač sadrži kopolimer etilen vinil acetata; i
Item 7. The use of any one of items 1 to 6, wherein the AAV vector is a pseudotyped AAV vector, preferably an AAV2/9 vector. 
AAV vektor iz bilo kojeg od patentnih zahtjeva 1 do 4, pri čemu je AAV vektor AAV2/9 vektor koji sadrži AAV2- derivirani genom u AAV9-deriviranoj kapsidi.
Step (i): reacting 4-hydroxy piperidine of formula (1) with cyclobutanone of formula (2) 
Korak (i): reakcija 4-hidroksi piperidina iz formule (1) s ciklobutanonom iz formule (2)
A kit according to claim 1 wherein the humanized anti-CD4 antibody comprises an H chain V domain defined by SEQ ID No: 1 and an L chain V domain defined by SEQ ID NO: 2. 
Komplet u skladu s patentnim zahtjevom 1, naznačen time što humanizirano protutijelo protiv CD4 sadrži V domenu lanca H, koju definira SEQ ID NO: 1, i V domenu lanca L, koju definira SEQ ID NO: 2.
In a first aspect, this invention is compounds of the formula where: X is L -Y-glutamyl or L -Y-glutamylglycyl; 
Razotkrivanje izuma u prvom aspektu, izum je spoj formule gdje. X je L-y-glutamil ili L-y-glutamilglicil;
A dry powder aerosol composition for use according to Claim 1 wherein the dry powder aerosol composition comprises particles at least 50% of which have an aerodynamic diameter in the range of from 1 µm to 5 µm. 
Suhi sastav praškastog aerosola za uporabu prema zahtjevu 1, naznačen time, da suhi sastav praškastog aerosola sadrži čestice od kojih najmanje 50% imaju aerodinamični promjer u rasponu od 1 um do 5 um.
Alternatively, component (III) may also comprise at least 4, preferably at least 10, more preferably at least 20 additional amino acid residues of the N-terminal sequence of GLP-1(7-37), correspondingly including all mammalian isoforms or—as disclosed herein—all functional variants, analogs or derivatives thereof. 
Fuzijski peptid prema patentnom zahtjevu 9 ili 10, naznačen time da komponenta (III) obuhvaća najmanje 4, poželjno najmanje 10, a još poželjnije najmanje 20 aminokiselinskih ostataka N-terminalne sekvence od GLP-2 kao u proglukagonu ili od GLP-1(7-37). t>&
In a particular embodiment, compound 6 has a diastereomeric purity greater than 70:30. 
Spoj u skladu s patentnim zahtjevom 6, naznačen time, da spoj 6 ima dijastereomernu čistoću veću od 70: 30.
Preferred hypolipidemic agents are pravastatin, lovastatin, simvastatin, atorvastatin, fluvastatin, cerivastatin, atavastatin and ZD-4522. 
Poželjna hipolipidemijska sredstva su pravastatin, lovastatin, simvastatin, atorvastatin, fluvastatin, cerivastatin, atavastatin i ZD-4522.